Table 3 Follow-up: complications, renal outcomes and death
From: Association of renal resistive indices with kidney disease progression and mortality
Variable | Total N = 192 | Patients with RRI < 0.7 N = 68 | Patients with RRI ≥ 0.7 N = 124 | P |
|---|---|---|---|---|
Complications during follow-up | ||||
Coronary event, n(%) | 31 (16.1) | 13 (19.1) | 18 (14.5) | 0.313 |
Stroke, n(%) | 8 (4.2) | 3 (4.4) | 5 (4) | 0.851 |
Heart failure, n(%) | 12 (6.3) | 4 (5.9) | 8 (6.5) | 0.915 |
Outcomes | ||||
Serum creatinine, mg/dL T2 Median (IQR) | 1.9 (1.1–4.5) | 1.2 (0.9–1.9) | 2.5 (1.5–5.9) | < 0.001 |
eGFR, mL/min/1.73m2 T2 Median (IQR) | 33.5 (10.3–60.8) | 61 (31–87) | 22.5 (8–42.8) | < 0.001 |
Doubling of serum creatinine, n(%) | 42 (21.9) | 6 (8.8) | 36 (29) | 0.001 |
Dialysis, n(%) | 40 (20.8) | 8 (11.8) | 32 (25.8) | 0.022 |
Duration of follow-up until dialysis, months Mean ± SD | 38.2 ± 25.4 | 63.5 ± 28.1 | 31.8 (20.6) | < 0.001 |
Death, n(%) | 54 (28.1) | 12 (17.6) | 42 (33.9) | 0.017 |
Cause of death, n(%) | ||||
• Cardiac cause | 26 (13.5) | 6 (8.8) | 20 (16.1) | 0.02 |
• Stroke | 1 (0.5) | 0 | 1 (0.8) | |
• Cancer | 13 (6.8) | 5 (7.4) | 8 (6.5) | |
• Infection | 3 (1.5) | 0 | 3 (2.4) | |
• COVID | 8 (4.2) | 0 | 8 (6.5) | |
• Bleeding | 1 (0.5) | 0 | 1 (0.8) | |
• Cirrhosis | 1 (0.5) | 1 (1.5) | 0 | |
• Trauma | 1 (0.5) | 0 | 1 (0.8) | |